Nyxoah Raises $3 Million from an At-the-Market Equity Offering

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Raises $3 Million from an At-the-Market Equity Offering 

Mont-Saint-Guibert, Belgium – March 27, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company raised $2.8 million in gross proceeds pursuant to the Company’s $50 million at-the-market ('ATM') program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at the time of the sale. The shares were purchased by historical Nyxoah shareholder Cochlear Limited, and the proceeds will be used for general corporate purposes.

The ordinary shares described above were sold pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-268955), previously filed with the Securities and Exchange Commission (“SEC”) on December 22, 2022, which became effective on January 6, 2023, and a prospectus supplement dated January 6, 2023 and the accompanying prospectus the Company filed with the SEC in connection with the offer and sale of the Company’s common stock pursuant to the Controlled Equity OfferingSM Sales Agreement, dated as of December 22, 2022 with Cantor Fizgerald & Co., as sales agent (prospectus@cantor.com).

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

FORWARD-LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

  • ENGLISH_ATM_FINAL


Nyxoah Raises $3 Million from an At-the-Market Equity Offering

THỦ THUẬT HAY

Hạnh phúc đơn giản lắm, chỉ cần học cách quên và tha thứ thôi

'Xuân có hoa bách hợp, thu có trăng. Hạ có gió mát, đông có tuyết. Trong lòng không có việc phải phiền lo mới chính là mùa đẹp của nhân gian. Nhớ những cái cần nhớ, quên những cái nên quên, sống cuộc sống cởi mở, trong

Đây là các cách để bạn hủy gói cước dịch vụ 4G của Viettel mới nhất

Ắt hẳn ai trong chúng ta ở đây đã ít nhất một lần vô cùng bực bội vì bị tự động gia hạn các gói cước 3G/4G của Viettel khi không còn nhu cầu sử dụng. Để tránh tình trạng này chúng ta phải hủy gói cước trước khi nó đến

Cách copy tất cả link trên Safari với iOS 15 để truy cập lại khi cần

Dùng Safari trên iPhone để duyệt web, có những lúc bạn mở rất nhiều tab khác nhau. Sau đây là cách copy tất cả link trên Safari với iOS 15 để truy cập lại khi cần nhé...

Hướng dẫn sử dụng chế độ “Dark Mode” hoàn thiện trên iOS 12

Chế độ Dark Mode thường sẽ thay đổi màu nền của các hoạt động hay ứng dụng sang màu tối để dễ theo dõi vào ban đêm và bảo vệ mắt người dùng. Trên hệ điều hành iOS, tính năng này có tên “Smart invert”. Chế độ này đã

Hướng dẫn kích hoạt bảo mật 2 lớp cho Apple ID

Xác thực 2 lớp là tầng bảo mật bổ sung được thiết kế để ngăn chặn truy cập trái phép vào tài khoản của bạn, đồng thời bảo vệ ảnh, tài liệu và các dữ liệu khác được lưu với Apple.

ĐÁNH GIÁ NHANH

Sơ lược về Laptop Surface mới: Đáng để chờ đợi

Có ba điều mà hầu hết mọi người đã nghe về máy tính xách tay Surface. Trước tiên, trông rất giống MacBook Air. Thứ hai, nó có vải bao bọc. Thứ ba, nó chạy phiên bản hệ điều hành được gọi là Windows 10 S.

Đánh giá camera iPhone 7 Plus: chưa đến mức quá tốt

Giao diện ứng dụng camera của iPhone 7 Plus. Ưu nhược điểm Với một chiếc smartphone trang bị hai camera (chưa...